安体舒通对慢性胆总管结扎肝硬化犬门脉高压和门体分流的影响

The effects of spironolactone on portal hypertension and portal-systemic shunt of cirrhotic dogs induced by chro- nic common bile duct ligation.

目的研究安体舒通对慢性胆总管结扎肝硬化犬门脉压力和门体分流的作用。方法用门静脉插管直接测压和９９ｍＴｃ－ＭＩＢＩ心肝放射性摄取比值（Ｈ／Ｌ）来评价安体舒通的作用。安体舒通口服每日２０ｍｇ／ｋｇ，连续四周。结果四周后１６只犬中１３只犬完成了研究。门脉压力从２５８７２±０．５０９６ｋＰａ下降为２４２０６±０．４７０４ｋＰａ（ｐ＜０．０５），Ｈ／Ｌ值从０３３±０．０６下降为０３０±０．０８（ｐ＜０．０５）。伴血浆容量明显减少，肝血流量无明显变化。结论安体舒通能降低肝硬化犬的门脉压力和门体分流，是治疗门脉高压的的有效药物。

Aims To study the effects of spironolactone on portal venous Pressure and portal-systemic shunt of cirrhotic dogs induced by chronic common bile duct ligation.Methods The portal venous pressure was determined directly and the portal-systemic shunt determined by 99mTc-MIBI heart-liver radioisotopic take-up ratio(H/L).Spironolactone was administrated orally 2.0mg/kg per day for four week.Results Of 16 cirrhotic dogs,13 finished the whole study.The fourweek administration of spironolactone made the portal venous pressure reduced from 2.5872±0.5096KPa to 2.4206±0.4704KPa(p<0.05),H/L value decreased from 0.33±0.06 to 0.30±0.08(p<0.05),associated with a Significant contraction of circulating plasma volume,while the hepatic blood flow remained unchanged.Conclusions Spironolactone can reduce the portal venous pressure and portal-systemic shunt of cirrhotic dogs,and is an effective drug for treating portal hypertensien.